MedTrace Logo

Safety and Efficacy of Combining nbUVB to Etanercept in Patients

NCT00640393 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2011-09-09

Study results available
· View outcomes & findings →

Summary

This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Etanercept

Etanercept 50 mg, subcutaneous (SC) injection.

DEVICE

nbUVB

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Innovaderm Research Inc.

    lead OTHER

Principal Investigators

  • Robert Bissonnette, MD · Innovaderm Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-02-28
Completion
2010-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640393 on ClinicalTrials.gov